Breaking News Instant updates and real-time market news.

RHHBY

Roche

$30.70

-0.26 (-0.84%)

07:13
10/05/16
10/05
07:13
10/05/16
07:13

Genentech granted Breakthrough Therapy Designation status for Actemra for GCA

Genentech, a member of the Roche Group, announced today that the FDA has granted Breakthrough Therapy Designation status to Actemra for giant cell arteritis, or GCA, a chronic, potentially life-threatening autoimmune condition. The disease is caused by inflammation of large and medium-sized arteries, most often in the head, but also in the aorta and its branches.

  • 19

    Oct

  • 06

    Nov

  • 10

    Nov

RHHBY Roche
$30.70

-0.26 (-0.84%)

09/01/16
BMOC
09/01/16
NO CHANGE
BMOC
Bristol-Myers has negative read through from Roche data, says BMO Capital
BMO Capital analyst Alex Arfaei says that the positive data on Roche's (RHHBY) TECENTRIQ for second line NSCLC is negative for Bristol-Myers' (BMY) cancer drug, Opdivo. The analyst does not think that TECENTRIQ's results will be superior to that of Opdivo, but he believes that Roche's drug appears to have "a significant" benefit in PD-L1 positive patients." He predicts that Roche's drug could take "meaningful market share, particularly outside of the U.S." The analyst keeps a Market Perform rating on Bristol-Myers.
09/07/16
09/07/16
NO CHANGE

BioLineRx partnering with Roche company in cancer therapy research
BioLineRx (BLRX) has entered into a collaboration with Genentech, a member of the Roche (RHHBY) Group, to support several Phase 1b studies investigating BioLineRx's BL-8040 in combination with Atezolizumab, Genentech's anti-PDL1 cancer immunotherapy, in multiple cancer indications. The Phase 1b studies will evaluate the clinical response, safety and tolerability of the combination of these therapies, as well as multiple pharmacodynamic parameters, in hematologic malignancies and solid tumors. Under the agreement, Genentech will sponsor and conduct several Phase 1b trials in multiple solid cancer indications. In addition, BioLineRx will sponsor and conduct a Phase 1b study in acute myeloid leukemia patients. The studies are designed to evaluate the safety and efficacy of the combination of BL-8040 and Atezolizumab. Upon completion of the studies, both parties will have the option to expand the collaboration to include a pivotal registration study. Additional details of the collaboration were not disclosed.
09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.

TODAY'S FREE FLY STORIES

RLJ

RLJ Lodging Trust

$23.60

-0.2 (-0.84%)

, FCH

Felcor Lodging

$7.32

-0.05 (-0.68%)

07:20
04/24/17
04/24
07:20
04/24/17
07:20
Conference/Events
RLJ Lodging Trust and Felcor Lodging to host joint conference call »

Joint Conference call to…

RLJ

RLJ Lodging Trust

$23.60

-0.2 (-0.84%)

FCH

Felcor Lodging

$7.32

-0.05 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 24

    Apr

  • 28

    Apr

AKTX

Akari Therapeutics

$20.50

4.13 (25.23%)

07:16
04/24/17
04/24
07:16
04/24/17
07:16
Hot Stocks
Akari: Interim Phase 2 PNH data demonstrate 'positive' response with Coversin »

Akari Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

WGO

Winnebago

$26.25

0.15 (0.57%)

07:15
04/24/17
04/24
07:15
04/24/17
07:15
Initiation
Winnebago initiated  »

Winnebago initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVX

Chevron

$104.89

0.01 (0.01%)

07:14
04/24/17
04/24
07:14
04/24/17
07:14
Periodicals
Chevron to sell Bangladesh gas fields to Himalaya Energy, Reuters says »

Chevron has agreed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 31

    May

QTS

QTS Realty Trust

$52.90

-0.14 (-0.26%)

07:12
04/24/17
04/24
07:12
04/24/17
07:12
Recommendations
QTS Realty Trust analyst commentary  »

QTS Realty Trust named…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

CARA

Cara Therapeutics

$16.53

-0.56 (-3.28%)

07:12
04/24/17
04/24
07:12
04/24/17
07:12
Hot Stocks
Cara Therapeutics announces 'positive' data from Phase 1 trial of CR845 »

Cara Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

STLD

Steel Dynamics

$35.37

0.46 (1.32%)

07:10
04/24/17
04/24
07:10
04/24/17
07:10
Upgrade
Steel Dynamics rating change  »

Steel Dynamics upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKS

AK Steel

$6.72

-0.1 (-1.47%)

07:10
04/24/17
04/24
07:10
04/24/17
07:10
Upgrade
AK Steel rating change  »

AK Steel upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    May

NUE

Nucor

$60.00

-0.35 (-0.58%)

07:10
04/24/17
04/24
07:10
04/24/17
07:10
Upgrade
Nucor rating change  »

Nucor upgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

X

U.S. Steel

$30.42

-0.09 (-0.29%)

07:10
04/24/17
04/24
07:10
04/24/17
07:10
Upgrade
U.S. Steel rating change  »

U.S. Steel upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

AKZOY

AkzoNobel

$27.96

-0.11 (-0.39%)

, PPG

PPG

$105.94

-0.43 (-0.40%)

07:09
04/24/17
04/24
07:09
04/24/17
07:09
Hot Stocks
Breaking Hot Stocks news story on AkzoNobel, PPG »

AkzoNobel confirms third…

AKZOY

AkzoNobel

$27.96

-0.11 (-0.39%)

PPG

PPG

$105.94

-0.43 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAGE

SAGE Therapeutics

$72.82

1.19 (1.66%)

07:09
04/24/17
04/24
07:09
04/24/17
07:09
Hot Stocks
SAGE Therapeutics appoints Michael Cloonan as Chief Business Officer »

Sage Therapeutics (SAGE)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOMA

XOMA

$7.73

0.26 (3.48%)

07:09
04/24/17
04/24
07:09
04/24/17
07:09
Hot Stocks
XOMA says X213 shown to be safe and effective in phase 2 study »

XOMA Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

AMDA

Amedica

$0.38

0.01 (2.70%)

07:08
04/24/17
04/24
07:08
04/24/17
07:08
Hot Stocks
Amedica announces regulatory clearance to market, sell Valeo in Australia »

Amedica Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSBC

HSBC

$39.94

-0.09 (-0.22%)

, JPM

JPMorgan

$84.52

-1.03 (-1.20%)

07:07
04/24/17
04/24
07:07
04/24/17
07:07
Periodicals
HSBC selected to advise on $100B Aramco IPO, Reuters reports »

HSBC (HSBC) has been…

HSBC

HSBC

$39.94

-0.09 (-0.22%)

JPM

JPMorgan

$84.52

-1.03 (-1.20%)

MS

Morgan Stanley

$41.80

-0.7 (-1.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 09

    May

  • 19

    May

  • 22

    May

  • 14

    Jul

  • 12

    Oct

  • 13

    Apr

  • 13

    Jul

  • 12

    Oct

AKER

Akers Biosciences

$1.80

0.1 (5.88%)

07:07
04/24/17
04/24
07:07
04/24/17
07:07
Hot Stocks
Akers Biosciences says digital apps approved by Apple Store »

Akers Biosciences …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHT

DHT Holdings

$4.60

-0.05 (-1.08%)

07:07
04/24/17
04/24
07:07
04/24/17
07:07
Hot Stocks
DHT Holdings announces delivery of two VLCCs from BW Group »

DHT Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFR

Colony Starwood Homes

$34.82

0.12 (0.35%)

07:07
04/24/17
04/24
07:07
04/24/17
07:07
Initiation
Colony Starwood Homes initiated  »

Colony Starwood Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 15

    May

AKZOY

AkzoNobel

$27.96

-0.11 (-0.39%)

, PPG

PPG

$105.94

-0.43 (-0.40%)

07:06
04/24/17
04/24
07:06
04/24/17
07:06
Hot Stocks
AkzoNobel says will 'carefully review' PPG's third unsolicited proposal »

Akzo Nobel N.V. (AKZOY)…

AKZOY

AkzoNobel

$27.96

-0.11 (-0.39%)

PPG

PPG

$105.94

-0.43 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLYA

Playa Hotels & Resorts

$10.26

-0.04 (-0.39%)

07:06
04/24/17
04/24
07:06
04/24/17
07:06
Initiation
Playa Hotels & Resorts initiated  »

Playa Hotels &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

FLR

Fluor

$50.58

0.09 (0.18%)

, BP

BP

$34.00

-0.15 (-0.44%)

07:06
04/24/17
04/24
07:06
04/24/17
07:06
Hot Stocks
Fluor awarded offshore compression platform FEED by BP »

Fluor (FLR) announced…

FLR

Fluor

$50.58

0.09 (0.18%)

BP

BP

$34.00

-0.15 (-0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

PRTK

Paratek Pharmaceuticals

$22.00

0.4 (1.85%)

07:05
04/24/17
04/24
07:05
04/24/17
07:05
Hot Stocks
Paratek, Zai Lab announce collaboration for Omadacycline in China »

Paratek Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRTK

Paratek Pharmaceuticals

$22.00

0.4 (1.85%)

07:04
04/24/17
04/24
07:04
04/24/17
07:04
Hot Stocks
Paratek highlights potential for omadacycline to provide cost savings vs. SOC »

Paratek Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BWLD

Buffalo Wild Wings

$161.75

-2 (-1.22%)

07:04
04/24/17
04/24
07:04
04/24/17
07:04
Hot Stocks
Buffalo Wild Wings announces filing of proxy materials »

Buffalo Wild Wings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

GWW

Grainger

$195.15

-0.81 (-0.41%)

07:04
04/24/17
04/24
07:04
04/24/17
07:04
Downgrade
Grainger rating change  »

Grainger downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 19

    Jul

  • 17

    Oct

  • 24

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.